All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Qingdi Quentin Li

Qingdi Quentin Li

Qingdi Quentin Li


National Cancer Institute, National Institutes of Health




Q. Quentin Li is a research scientist at the National Cancer Institute, National Institutes of Health, and was an assistant professor at the Mary Babb Randolph Cancer Center, West Virginia University Robert C. Byrd Health Sciences Center. He was a guest professor/visiting professor for six reputed universities in China. He obtained an M.D. from China and worked as dermatologist at Sun Yat-Sen University School of Medicine. He also received his M.S. in Microbiology & Immunology and Ph.D. in Pharmacology and Experimental Therapeutics from the University of Maryland School of Medicine, with postdoctoral training in Molecular and Cell Biology of Cancer in Medical Oncology Branch (formerly Medicine Branch) of the Center for Cancer Research at the National Cancer Institute. He is a member of the American Association for Cancer Research. He served as principal investigator on several grants funded by the National Institutes of Health and a pharmaceutical company. He was elected to Who’s Who in Medicine and Healthcare, Who’s Who in Science and Engineering, Who’s Who in America, and Who’s Who in the World in 2002 and 2003. He serves on the Editorial Board of 25 journals and is a reviewer for 55 scientific journals and a research & development foundation. He has authored over 100 peer-reviewed research articles and reviews and presented more than 60 papers at national and international scientific meetings


Research Interest

Photoimmunotherapy of cancer; Microorganisms & cancer; Cancer immunology; Chemokines & cancer; Immunopharmacology & Oncopharmacology; Molecular & cell biology of cancer; Cancer chemotherapy; New drug research & development; Natural products as anticancer agents; Apoptosis & cell cycle control in cancer; DNA damage repair & platinum drug resistance in carcinomas; Epigenetic modulation of DNA damage responses and DNA repair; Identification of biomarkers and epigenetic markers for diagnosis and treatment of carcinomas; Epigenetic regulation of gene expression in T cells and leukemic cells; Platinum and taxol drug resistance in lung cancer, ovarian cancer, bladder cancer, and other types of solid tumor.